## Mat '214, 1951, 1873; 132, 003

Spivack

10/016146

```
ACCESSION NUMBER:
                            2000:456866 CAPLUS
DOCUMENT NUMBER:
                           133:84239
TITLE:
                           Method of using an integrin antagonist and one or more
                           antineoplastic agents as a combination
                           therapy in the treatment of neoplasia
                           McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime
INVENTOR(S):
PATENT ASSIGNEE(S):
                           G. D. Searle & Co., USA
                           PCT Int. Appl., 220 pp.
SOURCE:
                           CODEN: PIXXD2
DOCUMENT TYPE:
                           Patent
LANGUAGE:
                           English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                        KIND
                               DATE
                                               APPLICATION NO.
                                                                  DATE
     WO 2000038665
                         A2
                               20000706
                                               WO 1999-US30670
                                                                  19991222
     WO 2000038665
                         А3
                               20001116
              AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
              CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
              IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
              MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
              DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
              CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                              20000706
     CA 2356462
                         AΑ
                                              CA 1999-2356462 19991222 .
     EP 1140193
                               20011010
                                                                 19991222
                         A2
                                              EP 1999-968529
              AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO
     JP 2002533387
                              20021008
                                               JP 2000-590619
                                                                 19991222
PRIORITY APPLN. INFO.:
                                           US 1998-113786P P \ 19981223
                                           WO 1999-US30670 W 19991222
     The present invention provides methods to treat or prevent neoplasia
AΒ
     disorders in a mammal using a combination of an integrin antagonist and an
     antineoplastic agent.
     50-18-0, Cyclophosphamide 51-21-8, 5-
     Fluorouracil 15663-27-1, Cisplatin
     23214-92-8, Doxorubicin 33069-62-4, Paclitaxel
     280105-13-7 280105-14-8 280105-17-1
     280105-18-2 280105-19-3
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
     (Uses)
         (integrin antagonist-antineoplastic agent combination for
        neoplasia treatment)
RN
     50-18-0 CAPLUS
CN
     2H-1,3,2-0xazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-,
     2-oxide (9CI)
                    (CA INDEX NAME)
```

51-21-8 CAPLUS 2,4(1H,3H)-Pyrimidinedione, 5-fluoro- (9CI) (CA INDEX NAME)

15663-27-1 CAPLUS RN Platinum, diamminedichloro-, (SP-4-2)- (9CI) (CA INDEX NAME) CN

ИНЗ 2+ Pt. NH3

23214-92-8 CAPLUS 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-RN CN

hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

33069-62-4 CAPLUS RN

Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS) -6, 12b-bis(acetyloxy) -12-(benzoyloxy)-CN 2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 11-dihydroxy-4a, 8, 13, 13tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RN 280105-13-7 CAPLUS

.beta.-Alanine, N-[3-amino-5-[(1,4,5,6-tetrahydro-5-hydroxy\*/, pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxy\*/, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 280105-14-8 CAPLUS
.beta.-Alanine, N-[3-[(hydroxyamino)carbonyl]-5-[(1,4,5,6-ter/////20-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloss)hydroxyphenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 280105-17-1 CAPLUS CN .beta.-Alanine, N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy// pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-, (CA INDEX NAME) (3R) - (9CI)

solute stereochemistry.

280105-18-2 CAPLUS "RN

.beta.-Alanine, N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-CN pyrimidinyl)amino]benzoyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

280105-19-3 CAPLUS RN

.beta.-Alanine, N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-CN pyrimidinyl)amino]benzoyl]glycyl-3-(5-bromo-3-chloro-2-hydroxyphenyl)-, (CA INDEX NAME) (3R) - (9CI)

Absolute stereochemistry.

USPATFULL ANSWER 9 OF 10 L65